Biora Therapeutics, Inc. (NASDAQ:BIOR) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET

Company Participants

Adi Mohanty – Chief Executive Officer

Eric d’Esparbes – Chief Financial Officer

Conference Call Participants

Julian Harrison – BTIG

Yuan Zhi – B. Riley

Operator

Greetings and welcome to the Biora Therapeutics Second Quarter 2022 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host Alexandra Schuman [ph]. Please go ahead.

Unidentified Company Representative

Thank you, operator. Good afternoon and welcome to Biora Therapeutics second quarter 2022 corporate update and financial results conference call. Joining me on the call are Adi Mohanty, Chief Executive Officer; and Eric d’Esparbes, Chief Financial Officer.

Before I turn the call over to Mr. Mohanty, I would like to remind you that today’s call will include forward-looking statements within the meaning of the federal securities laws, including, but not limited to the types of statements identified as forward-looking in our quarterly report on Form 10-Q that we will file later today and our subsequent reports filed with the SEC, which will all be available on our website in the Investors section.

These forward-looking statements represent our views only as of the date of this call and involve substantial risks and uncertainties, including many that are beyond our control. Please note that the actual results could differ materially from those projected in any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements as well as risks related to our business, please see the company’s periodic reports filed with the SEC.

With that, I will now turn the call over to Adi Mohanty, the CEO of Biora Therapeutics.

Adi Mohanty

Thanks, Alex, and thank you everyone for joining us. During the second quarter, we completed our transition from a diagnostics company into Biora Therapeutics, a biotherapeutics company that's working on changing the way large molecules can be delivered to patients with potentially game changing outcomes. Biora is much more resource efficient and making rapid progress in its development. We've continued to generate human safety and performance data with our targeted therapeutics program, where we recently shared top-line data from a human study demonstrating that the performance of our ingestible device is not impacted by food. Additionally, we recently concluded another study in active UC patients with outstanding results demonstrating the device functions as intended in these patients despite disease in the colon.